Methadone in the Treatment of Narcotic Addiction. References

1. Greenwood J. Creating a new drug service in Edinburgh. BMJ 1990;300:587-9.

2. Robinson GM, Thornton N. Methadone in general practice. NZ Med J 1994:Jan26

3. Wilson P, Watson R, Ralston GE. Methadone maintenance in general practice : patients, workload, and outcomes. BMJ 1994;309:641-4.

4. Dole VP, Nyswander ME. A medical treatment for diacetylmorphine (heroin) addiction. JAMA 1965;193:80-84.

5. Bickel WK, Stitzer ML, Bigelow GE, Liebson IA, Jasinski DR, Johnson RE. A Clinical trial of buprenorphine: Comparison with methadone in the detoxification of heroin addicts. Clinical Pharmacology and Therapeutics; 1988 43:72-78.

6. Tennant FS, Rawson RA, Pumphrey E, Seecof R. Clinical experience with levo-alpha-acetylmethadol (LAAM). Journal of Substance Abuse Treatment. 3(3):195-202, 1986.

7. Elias H. Substitute drug-assisted treatment of drug dependent patient in general practice. Fortschr-Med. 1990 Apr 30;108(13):256-8

8. Hartnoll RL, Mitchelson MC, Battersby A, Brown G, Ellis M, Fleming P, Hedley N. Evaluation of Heroin Maintenance in Controlled Trial. Arch Gen Psychiatry 1980 37:877-84.

9. Cowley G, Biddle NA, Murr A. A New Assault on Addiction. Newsweek, 1995

10. Grönbladh L, Öhlund LS, Gunne LM. Mortality in heroin addiction: impact of methadone treatment. Acta Psychiatr Scand 1990; 82: 223 - 227

11. Novick DM, Richman BL, Friedman JM, Friedman JE, Wilson JP, Townley A, Kreek MJ. The medical status of methadone maintenance patients in treatment for 11-18 years. Drug and Alcohol Dependence, 1993:33;235-245

12. Ward J, Mattick RP, Hall W. Key Issues In Methadone Maintenance Treatment. NSW University Press Ltd, 1992.

13. Goldstein A, Hansteen RW, Horns WH. Control of methadone dosage by patients: JAMA 234:734-737

14. Hargreaves WA. Methadone dosage and duration for maintenance treatment. In Cooper JR, Altman F, Brown BS Szechowicz D, (Eds) Research on the Treatment of Narcotic Addiction: State of the Art. Maryland: NIDA, US Department of Health and Human Sciences, 1

15. Havassy B, Hargreaves WA. Self-regulation of dose in methadone maintenance with contingent privileges. Addictive Behaviors, 1979; 4:31-38

16. Novick DM, Joseph H, Croxson TS, Salsitz EA, Wang G, Richman BL, Poretsky L, Keefe JB, Whimbey E. Absence of antibody to human immunodeficiency virus in long-term, socially rehabilitated methadone maintenance patients. Arch Intern Med. 150:15-25

17. Tennant FS. Inadequate Plasma Concentrations in Some High-Dose Methadone Maintenance Patients. Am J Psychiatry 1987; 144: 1349-1350.

18. Ball J, Ross A: The Effectiveness of Methadone Maintenance Treatment. Springer-Verlag, New York 1986. 242

19. McLellan AT, Arndt IO, Metzger DS, Woody GE, O'Brien CP. The Effects or Psychosocial Services in Substance Abuse Treatment. JAMA. 1993;269:1953-1959.

20. Drummer OH, Syrjanen M, Opeskin K, Cordner S. Deaths of heroin addicts starting on a methadone maintenance programme. Lancet 1990 Jan 13 [letter].

21. D'Aunno T, Vaughan TE. Variations in methadone treatment practices; results from a national study. JAMA. 1992;267:253-8.

22. Britton, BM. The privatisation of methadone maintenance; changes in risk behavior associated with cost related detoxification. Addiction Research. 2(2);171-181.

23. Senay EC, Barthwell A, Marks R, Bokos PJ. Medical Maintenance: An Interim Report. Journal of Addictive Diseases. 1994;13(3):65-9.

24. Ball J, Ross A: The Effectiveness of Methadone Maintenance Treatment. Springer-Verlag, New York 1986. p238

25. Senay EC, Barthwell AG, Marks R, Bokos P, Gillman D, White R. Medical Maintenance: A pilot Study. J Addictive Diseases; 1993:12(4):59-76.

26. Novick DM, Joseph II. Medical maintenance: the treatment of chronic opiate dependence in general medical practice. J. Subst. Abuse Treat. 1991 8;233-239

27. Byrne AJ. Results of survey of New South Wales methadone prescribers. [letter] Drug Alc Rev. (1995) 14, 239.

28. Emit d.a.u. Assays, Syva Company, San Jose, CA 95135, USA.

29. Swensen G, Ilett KF et al. Patterns of drug use by participants in the Western Australian methadone program, 1984-1991. Med J Aust 1993; 159: 373-376.

30. Ray WA, Griffin MR, Downey W. Benzodiazepines of long and short elimination half-life and the risk of hip fracture. JAMA 1989; 262: 3303-3307.

31. Lucki I et al. Chronic use of benzodiazepines and psychomotor and cognitive test performance. Psychopharmacology 1986; 88: 426-33.

32. Cumming R, Klineberg R. Psychotropics, thiazide diuretics and hip fractures in the elderly. Med J Aust;158:414-17.

33. Hartnoll RL, Mitchelson MC, Battersby A, Brown G, Ellis M, Fleming P, Hedley N. Evaluation of Heroin Maintenance in Controlled Trial. Arch Gen Psychiatry 1980 37:877-84.

34. Thomas BL. Methadone-associated gynecomastia. [letter] N Engl J Med. 1975.

35. Cicero TJ, Bell RD, Wiest WG et al. Function of the male sex organs in heroin and methadone users. N Engl J Med 292:882-7.

36. Martindale. The Extra Pharmacopoeia. Ed. Reynolds JEF. 1989; p1311.

37. De Quincey T. Confessions of an English Opium Eater. Penguin Classics edited by Alethea Hayter. 97,122.

38. Martindale. The Extra Pharmacopoeia. Ed. Reynolds JEF. 1989; p1308.

39. Maany I, Dhopesh V, Arndt IO, Burke W, Woody G, O'Brien CP. Increase in desipramine serum levels associated with methadone treatment. Am J Psychiatry. 1989 (Dec);146(12);1611-3.

40. Kreek MJ. Methadone in treatment : Physiology and pharmacological issues. In Dupont, Goldstein, O'Donnell & Brown, (Eds), Handbook on Drug Abuse. 1979 USA: National Institute on Drug Abuse.

41. Umbricht-Schneiter A, Ginn DH, Pabst KM, Bigelow GE. Providing Medical Care to Methadone Clinic Patients: Referral vs On-Site Care. Am J Public Health 1994;84:207-210.